Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies
- 30 November 2010
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 46 (17) , 3095-3101
- https://doi.org/10.1016/j.ejca.2010.09.016
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy resultBritish Journal of Cancer, 2010
- Mutation analysis of the MSMB gene in familial prostate cancerBritish Journal of Cancer, 2009
- Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal studyBritish Journal of Cancer, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screeningBritish Journal of Cancer, 2009
- Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysisInternational Journal of Cancer, 2009
- Height and prostate cancer risk: A large nested case-control study (ProtecT) and meta-analysisCancer Epidemiology, Biomarkers & Prevention, 2008
- Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trialBMJ, 2007
- Quality improvement report Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study Commentary: presenting unbiased information to patients can be difficultBMJ, 2002